RESUMEN
Background: It is important to understand how consultation time relates to patient satisfaction, as these two variables have not been extensively studied together. Objective: To determine the correlation between consultation time and patient satisfaction in primary care settings in Mexico. Materials and methods: Cross-sectional, observational, and analytical study that included patients over 18 years old. Time was measured using a stopwatch, and satisfaction was assessed using the Patient Doctor Relationship Questionnaire (PDRQ-9). The correlation between both variables was analyzed using the Spearman test, and multiple linear regression was employed to associate satisfaction with the consultation. Results: A total of 115 participants were included. The average consultation duration was 12.1 minutes, and 74% of patients reported that the consultation time was adequate. A weak positive correlation (p < 0.001, r = 0.38) was found between actual consultation time and satisfaction. Multiple linear regression demonstrated that for every minute increase in consultation time, level of satisfaction increased in 0.04 units (p = 0.001, CI95%: 0.016-0.063). Conclusion: Most patients reported satisfaction with the duration of their medical consultation, and longer consultation times were associated with higher satisfaction levels.
Introducción: es importante conocer cómo el tiempo de la consulta se relaciona con la satisfacción del paciente, ya que son dos variables que no se han estudiado a profundidad de forma conjunta. Objetivo: determinar la correlación que existe entre el tiempo de consulta y la satisfacción del paciente en un primer nivel de atención en México. Material y métodos: estudio transversal, observacional y analítico que incluyó a pacientes mayores de 18 años. Se midió el tiempo con cronómetro, así como la satisfacción mediante el cuestionario Patient Doctor Relationship Questionnaire (PDRQ-9). Se analizó la correlación entre ambas variables con la prueba de Spearman y para asociar la satisfacción con la consulta se empleó regresión lineal múltiple. Resultados: se incluyeron 115 participantes. La duración media de la consulta fue de 12.1 minutos y el 74% de los pacientes indicó que el tiempo de consulta les pareció adecuado. Se encontró una correlación positiva leve (p < 0.001, r = 0.38) entre el tiempo real de la consulta y la satisfacción. Mediante la regresión lineal múltiple se demostró que, por cada minuto de aumento en la consulta, el índice de satisfacción aumentaba en un 0.04 (p = 0.001, IC95%: 0.016-0.063). Conclusión: la mayoría de los pacientes refieren estar satisfechos con la duración de la consulta médica; sin embargo, a mayor duración de la consulta los pacientes muestran mayor satisfacción.
Asunto(s)
Satisfacción del Paciente , Derivación y Consulta , Humanos , Adolescente , Estudios Transversales , Encuestas y Cuestionarios , Atención Primaria de SaludRESUMEN
The study aims to determine SARS-CoV-2 RNA in sewage of Cancun wastewater treatment plants, the main touristic destination of Mexico, and to estimate the infected persons during the sampling period. SARS-CoV-2 RNA traces were detected in the inlet of the five plants during almost all the sampling months. However, there is no presence of SARS-CoV-2 RNA traces in the effluent of the five WWTPs during the study period. ANOVA analysis showed differences in the concentrations of RNA traces of SARS-CoV-2 between the sample dates, but no differences were found from one WWTP to another. Estimated infected individuals by Markov chain Monte Carlo simulation are higher (between 77% and 91%) than the cases reported by the health authority. Wastewater monitoring and the estimation of infected individuals are a helpful tool, because estimation provides early warning signs on how broadly SARS-CoV-2 is circulating in the city, and led to the authorities to take measures wisely. PRACTITIONER POINTS: There is no presence of SARS-CoV-2 RNA traces in the effluent of the facilities, suggesting the effectiveness of treatment. Surveillance of viral RNA concentrations at treatment plants revealed presence in the influent of five plants Estimated infected individuals by MCMC simulation are higher than cases reported by health authority Environmental surveillance approach in wastewater influent is helpful to identify the clusters and to take informed decisions.
Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , SARS-CoV-2/genética , COVID-19/epidemiología , Aguas Residuales , ARN Viral/genética , México , Región del CaribeRESUMEN
INTRODUCTION: Calcium channel blockers (CCB) are a leading cause of ingestion-associated fatality. Angiotensin-converting enzyme inhibitor (ACEi) overdose as part of co-ingestion is common and associated with refractory shock. Treatment options to manage this profound vasoplegia are limited. We describe the first case of use of newly formulated Angiotensin II for treatment of severe ACEi and CCB poisoning. CASE REPORT: A 57-year-old man presented after suicide attempt by ingesting 20 tablets each of amlodipine 10 mg and benazepril 20 mg. His hypotension was initially managed with 35 mL/kg of crystalloid, norepinephrine, and hyperinsulinemic euglycemic therapy (HIET). His hemodynamics further deteriorated, and he developed lactic acidosis, electrolyte derangements, and renal dysfunction. Further complications of his ingestion included cardiac arrest, subsequent requirement for emergency cricothyrotomy, and renal replacement therapy. Maximal hemodynamic support with HIET therapy insulin drip 4.4 units/kg/hour, norepinephrine 2 mcg/kg/min, epinephrine 1 mcg/kg/min, vasopressin .06 units/hour, and intravenous lipid emulsion was unsuccessful. Ang II was started and titrated to maximal doses with dramatic improvement in hemodynamics. Within hours of starting Ang II, epinephrine was stopped and norepinephrine decreased by 50%. He was downgraded from the intensive care unit without any ongoing end-organ dysfunction. DISCUSSION: Isolated CCB overdoses have high complication rates and well-established treatments. Therefore, management of CCB and ACEi co-ingestion is typically driven by CCB poisoning algorithm. There are multiple reports of CCB and ACEi co-ingestions causing treatment-refractory shock. Therapeutic options are limited by toxicities and availability of salvage therapies. Ang II is a safe and highly effective option to manage these patients.
RESUMEN
BACKGROUND AND OBJECTIVE: Therapeutic inertia (TI) is the lack of initiation or intensification of treatment when indicated. It contributes to the fact that more than a third of people with type 2 diabetes mellitus (T2D) do not have adequate metabolic control. We set out to analyze the impact of TI during 4 years of follow-up in a cohort of T2D and its possible variables. MATERIALS AND METHODS: Prospective cohort study of a cohort of 297 TD2 patients. We considered TI when treatment was not modified during the 4 years, despite poor control. We contemplate uncontrolled those that did not meet their individualized HbA1c target. RESULTS: Uncontrolled patients: 87; age: 62.2⯱â¯9.2; 58.7% men. We consider TI in 41.6% of the patients. Average HbA1c 8.22% in patients with treatment intensification of which 43.1% achieved their HbA1c goal, 29.8% were on monotherapy at the beginning, 29.8% double, 36.2% triple and 2,1% in quadruple therapy. There was more change in treatment in people with obesity (67.6 vs. 34.6%; Pâ¯<â¯0.01) and the 6 of the study patients with cardiovascular events (Pâ¯<â¯0.05). Metformin was part of the treatment in 97.1% of IT cases (vs. 76.6%; Pâ¯<â¯0.01). Achievement of the HbA1c target was higher in patients receiving iSGLT2 (0 vs. 68.4%; Pâ¯<â¯0.001). CONCLUSIONS: In 2 out of 5 uncontrolled T2D patients, the treatment was not changed; this was more evident in those patients treated with metformin. Patients with obesity and presence of cardiovascular events seem to protect against IT. Those who were on iSGLT2 have an advantage in meeting their HbA1c target.
Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Metformina , Anciano , Glucemia/metabolismo , Estudios de Cohortes , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Hemoglobina Glucada/análisis , Control Glucémico , Humanos , Hipoglucemiantes/uso terapéutico , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Obesidad/complicaciones , Estudios ProspectivosRESUMEN
Paraneoplastic syndromes, induced by an immunological cross-reaction or hormone/peptide secretion, are an atypical presentation of tumors. Some tumors, such as small cell lung cancer and bronchial carcinoid, can be adrenocorticotropic hormone (ACTH) secreting tumors. Less commonly, parotid acinic cell carcinoma can be ACTH-secreting tumor leading to Cushing's syndrome. Few literature cases have described ACTH related paraneoplastic syndrome of parotid adenocarcinoma. Because of the rarity of the condition, little is known about the management and prognosis of this phenomenon. In this report, we highlighted the case of a 59-year-old male with a past medical history of parotid adenocarcinoma treated with surgery, chemotherapy, and radiation therapy presented with clinical and biochemical signs of hyperaldosteronism. Abdominal ultra-sound, computed tomography, and magnetic resonance imaging showed hepatic mass. Liver biopsy with immunohistochemistry confirmed the presence of parotid adenocarcinoma secreting ACTH. He is on paclitaxel and carboplatin medication with good clinical response.
Asunto(s)
Síndrome de ACTH Ectópico , Carcinoma de Células Acinares , Síndrome de Cushing , Síndromes Paraneoplásicos , Síndrome de ACTH Ectópico/diagnóstico , Síndrome de ACTH Ectópico/etiología , Hormona Adrenocorticotrópica , Carcinoma de Células Acinares/complicaciones , Carcinoma de Células Acinares/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Síndromes Paraneoplásicos/complicaciones , Síndromes Paraneoplásicos/etiologíaRESUMEN
ANTECEDENTES Y OBJETIVO: La enfermedad cardiovascular supone una de las principales complicaciones de las personas con diabetes tipo 2 (DM2). La guía ESC/ESA 2019 de lípidos ha supuesto un cambio en el control de la dislipidemia. Analizamos la evolución del perfil lipídico, el cumplimiento de los objetivos de colesterol ligado a lipoproteínas de baja densidad (c-LDL), cómo clasifica a los pacientes y el impacto de esta guía en el control lipídico en pacientes con DM2. MATERIALES Y MÉTODOS: Estudio de cohortes prospectivo de 2017 a 2020 de una cohorte de 297 DM2 de un total de 1.229 (nivel de confianza del 95%). Clasificamos a los pacientes en función de su riesgo cardiovascular y si cumplían o no su objetivo de LDL. RESULTADOS: Edad 62,58±10,68 años; 52,79% varones. Niveles de c-LDL medio 116,2 al inicio y 100,2mg/dl a los 4 años (p<0,001). Cumplían su objetivo individualizado de c-LDL después de la publicación de la guía 57 (21,67%) pacientes. Hubo más controlados que eran menores de 65 años (57,9 vs. 36,9%; p<0,01; RR 0,83), varones (66,7 vs. 49,5%; p<0,05; RR 0,86) y fumadores (17,5 vs. 7,8%; p<0,05). El 74,23% tenía un riesgo cardiovascular alto y un objetivo c-LDL<70mg/dl. CONCLUSIONES: Desde la publicación de la guía de lípidos ESC/ESA 2019 se observa un descenso en los niveles de c-LDL. Aun así, solo uno de cada 5 pacientes cumple su objetivo individualizado de c-LDL. Presentaron ventajas por cumplir su objetivo los pacientes de sexo masculino, menores de 65 años y fumadores. La mayoría de los pacientes con DM2 tienen un riesgo cardiovascular alto y el objetivo de c-LDL predominante es inferior a 70mg/dl.
BACLGROUND AND OBJETIVE: Cardiovascular disease is one of the main complications of people with type 2 diabetes (T2D). The ESC/ESA 2019 lipid guide has led to a change in dyslipidemia control. We analyze the evolution of the lipid profile, the fulfillment of the low-density cholesterol (LDL-C) targets, how patients are classified and the impact of this guide on lipid control in T2D patients. MATERIALS AND METHODS: A prospective cohort study from 2017 to 2020 from a cohort of 297 T2D out of a total of 1229 (95% confidence level). We classified patients according to their cardiovascular risk and whether they met or not their LDL-C goal. RESULTS: Age 62.58±10.68 years; 52.79% men. Mean LDL-C levels 116.2 at baseline and 100.2mg/dL at 4 years (P<.001). They met their individualized LDL-C target after publication of the guide: 57 (21.67%). There were more controls who were under 65 years (57.9 vs. 36.9%; P<.01; RR 0.83), men (66.7 vs. 49.5%; P<.05; RR 0.86) and smokers (17.5 vs. 7.8%; P<.05). A percentage of 74.23 had a high cardiovascular risk and a target LDL-C<70mg/dL. CONCLUSIONS: Since the publication of the ESC/ESA 2019 lipid guide, a decrease in LDL-C levels has been observed. Only one in 5 patients fulfill their individualized LDL-C target. Male patients, under 65 years of age and smokers presented an advantage in meeting their goal. Most T2D patients have a high cardiovascular risk, and the predominant LDL-C target is less than 70mg/dL.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Ciencias de la Salud , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/complicaciones , Dislipidemias/epidemiología , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Estudios Prospectivos , Factores de RiesgoRESUMEN
Various populations of cells are recruited to the heart after cardiac injury, but little is known about whether cardiomyocytes directly regulate heart repair. Using a murine model of ischemic cardiac injury, we demonstrate that cardiomyocytes play a pivotal role in heart repair by regulating nucleotide metabolism and fates of nonmyocytes. Cardiac injury induced the expression of the ectonucleotidase ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which hydrolyzes extracellular ATP to form AMP. In response to AMP, cardiomyocytes released adenine and specific ribonucleosides that disrupted pyrimidine biosynthesis at the orotidine monophosphate (OMP) synthesis step and induced genotoxic stress and p53-mediated cell death of cycling nonmyocytes. As nonmyocytes are critical for heart repair, we showed that rescue of pyrimidine biosynthesis by administration of uridine or by genetic targeting of the ENPP1/AMP pathway enhanced repair after cardiac injury. We identified ENPP1 inhibitors using small molecule screening and showed that systemic administration of an ENPP1 inhibitor after heart injury rescued pyrimidine biosynthesis in nonmyocyte cells and augmented cardiac repair and postinfarct heart function. These observations demonstrate that the cardiac muscle cell regulates pyrimidine metabolism in nonmuscle cells by releasing adenine and specific nucleosides after heart injury and provide insight into how intercellular regulation of pyrimidine biosynthesis can be targeted and monitored for augmenting tissue repair.
Asunto(s)
Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , Hidrolasas Diéster Fosfóricas/metabolismo , Pirimidinas/biosíntesis , Pirofosfatasas/metabolismo , Regeneración , Transducción de Señal , Adenosina Monofosfato/genética , Adenosina Monofosfato/metabolismo , Adenosina Trifosfato/genética , Adenosina Trifosfato/metabolismo , Animales , Lesiones Cardíacas/genética , Lesiones Cardíacas/metabolismo , Ratones , Hidrolasas Diéster Fosfóricas/genética , Pirofosfatasas/genéticaRESUMEN
BACKGROUND AND OBJECTIVE: Cardiovascular disease is one of the main complications of people with type 2 diabetes (T2D). The ESC/ESA 2019 lipid guide has led to a change in dyslipidemia control. We analyze the evolution of the lipid profile, the fulfillment of the low-density cholesterol (LDL-C) targets, how patients are classified and the impact of this guide on lipid control in T2D patients. MATERIALS AND METHODS: A prospective cohort study from 2017 to 2020 from a cohort of 297 T2D out of a total of 1229 (95% confidence level). We classified patients according to their cardiovascular risk and whether they met or not their LDL-C goal. RESULTS: Age 62.58±10.68 years; 52.79% men. Mean LDL-C levels 116.2 at baseline and 100.2mg/dL at 4 years (P<.001). They met their individualized LDL-C target after publication of the guide: 57 (21.67%). There were more controls who were under 65 years (57.9 vs. 36.9%; P<.01; RR 0.83), men (66.7 vs. 49.5%; P<.05; RR 0.86) and smokers (17.5 vs. 7.8%; P<.05). A percentage of 74.23 had a high cardiovascular risk and a target LDL-C<70mg/dL. CONCLUSIONS: Since the publication of the ESC/ESA 2019 lipid guide, a decrease in LDL-C levels has been observed. Only one in 5 patients fulfill their individualized LDL-C target. Male patients, under 65 years of age and smokers presented an advantage in meeting their goal. Most T2D patients have a high cardiovascular risk, and the predominant LDL-C target is less than 70mg/dL.
Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Dislipidemias , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Anciano , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/complicaciones , Dislipidemias/complicaciones , Dislipidemias/epidemiología , Femenino , Humanos , Lípidos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores de RiesgoRESUMEN
Two new species of Neocarus (Opilioacarida: Opilioacaridae), N. haicolous n. sp. and N. queretanus n. sp., are described from mesophyll and pine-oak forests in the state of Querétaro, central Mexico. One species was described from adults and tritonymphs. Distribution and habitat preferences of all known collections of Opilioacarida are reviewed. In Mexico, they have been collected in all habitats, from semideserts areas to tropical forest and from to sea level in dunes to high temperate and cloud forest.
Asunto(s)
Ácaros y Garrapatas , Pinus , Animales , México , Ecosistema , BosquesRESUMEN
Introducción: Solo el 60 por ciento de los pacientes en tratamiento con antagonistas de la vitamina K (AVK) están controlados. Objetivos: A nalizar una cohorte de pacientes anticoagulados para valorar su grado de control y su evolución a los 2 años, tras una intervención formativa breve. Métodos: Estudio longitudinal, observacional, retrospectivo de 157 anticoagulados con AVK. Se recogieron datos sociodemográficos, comorbilidades, motivo de prescripción del AVK y grado de control basal y tras 2 años de seguimiento. Utilizamos 2 métodos de valoración diferentes: Rosendaal y método directo (porcentaje de INR-Razón Normalizada Internacional- en rango). Asimismo, establecimos correlaciones temporales intramétodo. Resultados: El grado de control pasó del 47,3 por ciento al 53,5 por ciento a los 2 años, según Rosendaal (p= 0,52), y del 39,5 por ciento al 53,5 por ciento según el método directo (p< 0,05). El tiempo en rango terapéutico fue del 63,1 ±19,9 por ciento al inicio y 65 ±19,2 por ciento al final del seguimiento. La correlación entre los 2 controles fue positiva para ambos métodos (Rosendaal: 0,23; método directo: 0,33). El análisis multivariante fue significativo para el sexo masculino y para un objetivo diferente de 2,5-3,5 (odds ratio: 2,22 y 2,73, respectivamente). Conclusiones: El control del INR mejoró a los 2 años de seguimiento tras la actividad formativa. La evolución del grado de control de cada paciente es parcialmente predecible. El peor control se asoció al sexo femenino y al objetivo de INR de 2,5-3,5. El control mejora 2,22 veces en los varones y 2,73 veces en quienes no tienen un INR objetivo de 2,5-3,5(AU)
Introduction: Only 60 percent of patients on treatment with vitamin K antagonists (AVK) are controlled. Objectives: We proposed to analyze a cohort of anticoagulated patients to assess their degree of control and their evolution at 2 years, after a brief training intervention. Methods: Longitudinal, observational, retrospective study of 157 anticoagulated with AVK. Sociodemographic data, comorbidities, reason for VKA prescription and degree of baseline control were collected and after 2 years of follow-up. We use 2 different valuation methods: Rosendaal and direct method (INR percentage -International Normalized Ratio- in range). Likewise, we established intra-method temporal correlations. Results: The degree of control went from 47.3 percent to 53.5 percent at 2 years, according to Rosendaal (p = 0.52), and from 39.5 percent to 53.5 percent according to the direct method (p<0.05). The time in the therapeutic range was 63.1±19.9 percent at the start and 65±19.2 percent at the end of the follow-up. The correlation between the 2 controls was positive for both methods (Rosendaal: 0.23; direct method:0.33). The multivariate analysis was significant for males and for a target other than 2.5-3.5(odds ratio: 2.22 and 2.73, respectively). Conclusions: INR control improved after 2 years of follow-up after training activity. The evolution of the degree of control of each patient is partially predictable. The worst control was associated with female sex and the INR goal of 2.5-3.5. Control improves 2.22 times in males and 2.73 times in those without a target INR of 2.5-3.5(AU)
Asunto(s)
Humanos , Masculino , Femenino , Relación Normalizada Internacional , Estudios Retrospectivos , Estudios de Cohortes , Estudios LongitudinalesRESUMEN
Introducción y objetivos: El uso de anticoagulantes para prevenir eventos embólicos en España es muy elevado, tendiendo a un aumento progresivo. Por ello pretendemos analizar la mortalidad de los pacientes tratados con anticoagulantes antagonistas de la vitamina K (AVK) de un área metropolitana de Granada, en 2 años no consecutivos.Pacientes y métodos: Estudio longitudinal, observacional, retrospectivo de 205 pacientes tratados con AVK. Se recogieron datos sociodemográficos, condiciones clínicas previas, patología causante del tratamiento AVK, grado de control y la mortalidad a 2 años del inicio del estudio.ResultadosEdad media, 76±11,8años (57,56% mujeres). La mortalidad a los 2 años fue del 22,4%, con un aumento significativo en función de la edad (p<0,001) y los años de tratamiento (p<0,001). Los pacientes con demencia (p<0,05), con enfermedad renal crónica (p<0,01) o con enfermedad pulmonar obstructiva crónica (p<0,01) presentaron también mayor mortalidad. El análisis multivariante demostró efecto significativo de la enfermedad renal crónica (odds ratio=4,075), la enfermedad pulmonar obstructiva crónica (odds ratio=3,694) y los años de tratamiento (odds ratio=1,236).ConclusionesA los 2 años de seguimiento, fallecieron uno de cada 5 pacientes tratados con AVK y se asociaron independientemente a este aumento la presencia de enfermedad renal crónica, enfermedad pulmonar obstructiva crónica y un mayor tiempo de tratamiento. La mayoría de los pacientes estaban anticoagulados por una fibrilación auricular, tenían una edad avanzada y una alta prevalencia de comorbilidades. (AU)
Introduction and objectives: The use of anticoagulants to prevent embolic events in Spain is very high, tending to a progressive increase. For this reason, we intend to analyse the mortality of patients from a metropolitan area of Granada treated with vitamin K antagonist anticoagulants (VKA), over 2 non-consecutive years.Patients and methods: Longitudinal, observational, retrospective study of 205 patients treated with VKA. Sociodemographic data, previous clinical conditions, pathology causing VKA treatment, degree of control and mortality were collected 2 years after the start of the study.ResultsAverage age, 76±11.8 years (57.56% women). Two-year mortality was 22.4%, with a significant increase depending on age (p<.001) and years of treatment (p<.001). Patients with dementia (p<.05), with chronic kidney disease (p<.01) or with chronic obstructive pulmonary disease (p<.01) also presented higher mortality. Multivariate analysis showed significant effect of chronic kidney disease (odds ratio=4.075), chronic obstructive pulmonary disease (odds ratio=3.694), and years of treatment (odds ratio=1.236).ConclusionsAt 2 years of follow-up, 1 in 5 patients treated with VKA died. The presence of chronic kidney disease, chronic obstructive pulmonary disease and a longer treatment time were independently associated with this increase of mortality. Most of the patients were anticoagulated by atrial fibrillation, they were elderly and had a high prevalence of comorbidities. (AU)
Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Administración Oral , Anticoagulantes/uso terapéutico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Primeros Auxilios , Vitamina K , Estudios de Seguimiento , Estudios Retrospectivos , Estudios LongitudinalesRESUMEN
OBJECTIVE: To determine the effect of fraction of inspired oxygen (FiO2) on intrapulmonary shunt fraction as measured by F-shunt in ponies during isoflurane anaesthesia. STUDY DESIGN: Prospective, randomized clinical study. ANIMALS: A group of 23 adult Shetland ponies undergoing a total of 32 anaesthetic procedures. METHODS: Ponies were premedicated intravenously (IV) with detomidine (0.01 mg kg-1) and either morphine (0.1 mg kg-1) or butorphanol (0.02 mg kg-1). Anaesthesia was induced with ketamine (2.2 mg kg-1) and midazolam (0.07 mg kg-1) administered IV. Ponies were randomly allocated to maintenance of anaesthesia with isoflurane in oxygen (group TH; FiO2 = 0.95) or a mixture of oxygen and medical air (group TL; FiO2 = 0.65); all ponies were given a constant rate of infusion of detomidine. Animals were mechanically ventilated to maintain PaCO2 between 40 and 50 mmHg. Arterial blood gas analysis was performed every 30 minutes. The F-shunt equation was calculated for each time point T0, T30, T60 and T90. Data were analysed using linear mixed model analysis and presented as mean ± standard deviation (p < 0.05). RESULTS: PaO2 was greater in group TH than in group TL (TH: 406 ± 90, 438 ± 83, 441 ± 69 and 464 ± 53 mmHg versus TL: 202 ± 90, 186 ± 84, 172 ± 85 and 191 ± 98 mmHg at T0, T30, T60 and T90, respectively; p < 0.0001). In TH, F-shunt was < TL. Significant differences were found at T60 (TH: 13.2% ± 4.3 versus TL: 19.4% ± 8.3; p = 0.016) and T90 (TH: 11.7% ± 3.5 versus TL: 18.6% ± 9.5; p = 0.036). CONCLUSIONS AND CLINICAL RELEVANCE: Our findings do not support a beneficial effect of using a reduced FiO2 to improve oxygenation in anaesthetized and mechanically ventilated Shetland ponies.
Asunto(s)
Caballos , Isoflurano , Animales , Oxígeno , Presión Parcial , Estudios Prospectivos , Respiración Artificial/veterinariaRESUMEN
OBJECTIVE: To use American College of Veterinary Internal Medicine (ACVIM) criteria to evaluate a high-definition oscillometric (HDO) blood pressure monitoring device versus invasive blood pressure (IBP) measurement in normotensive rabbits anaesthetized with two different anaesthetic protocols. STUDY DESIGN: Prospective experimental study. ANIMALS: A group of 20 healthy adult New Zealand White rabbits weighing 4.36 ± 0.37 kg (mean ± standard deviation). MATERIALS AND METHODS: Rabbits were premedicated with butorphanol 0.5 mg kg-1 and midazolam 0.5 mg kg-1 subcutaneously (SC, group BMA) or ketamine 25 mg kg-1 and medetomidine 0.4 mg kg-1 SC (group KM). Anaesthesia was induced with alfaxalone administered intravenously (group BMA) or isoflurane by face mask (group KM) and maintained with isoflurane in oxygen. IBP was measured from the central auricular artery. The cuff for the HDO monitor was placed distal to the left elbow and distal to the left tarsus. Agreement between invasive and HDO measurements was evaluated using Bland-Altman method. RESULTS: In group KM there was better agreement between the HDO device and IBP when the cuff was placed on the thoracic limb, with 100% and 91% of the readings for mean (MAP) and diastolic arterial pressure (DAP), respectively, within 10 mmHg of the IBP measurements. The agreement, although worse, also met the ACVIM criteria for systolic arterial pressure (SAP; 53% of the readings within 10 mmHg). In group BMA, the device met the criteria with the cuff on the thoracic limb only, and only for MAP and DAP (73% and 75% of the measurements within 10 mmHg of the IBP, respectively) but not for SAP (12%). CONCLUSION AND CLINICAL RELEVANCE: The HDO device met most of the ACVIM criteria for noninvasive blood pressure measurement in anaesthetized rabbits, specifically when the cuff was placed distal to the elbow and the anaesthetic protocol included ketamine and medetomidine.
Asunto(s)
Anestésicos , Presión Arterial , Presión Sanguínea , Anestésicos/farmacología , Animales , Arterias , Presión Sanguínea/efectos de los fármacos , Determinación de la Presión Sanguínea/veterinaria , Monitores de Presión Sanguínea/veterinaria , Estudios Prospectivos , ConejosRESUMEN
La candidiasis es una enfermedad micótica debida a levaduras pertenecientes al género Candida. Dentro del gran conjunto de microorganismos que colonizan al ser humano, Candida albicans es el agente etiológico más comúnmente detectado ya que habita como comensal en las superficies mucosas y la piel. C. albicans participa en procesos de fermentación de azúcares y asimilación de nutrientes, pero, en algunas ocasiones se relaciona con procesos patológicos. En los últimos años los avances tecnológicos y médicos; así como el aumento en la incidencia de infecciones por el virus de la inmunodeficiencia humana, el auge creciente de la terapia inmunomoduladora y el uso de antibióticos de amplio espectro durante largos períodos de tiempo se han convertido en los factores de riesgo más importantes para la creciente incidencia de infecciones por microorganismos del género Candida. Debido a esto, resulta imperativo el conocimiento de esta enfermedad y sus formas clínicas más importantes, así como el abordaje diagnóstico y el tratamiento actual; información que recolectamos en este documento para brindar una visión general sobre esta patología(AU)
Candidiasis is a fungal disease caused by yeasts belonging to the genus Candida. Within the large group of microorganisms that colonize humans, candida albicans is the most commonly detected etiological agent since it inhabits mucosal surfaces and skin as a commensal. C. albicans participates in sugar fermentation processes and assimilation of nutrients but, on some occasions, it is related to pathological processes. In recent years, technological and medical advances; As well as the increase in the incidence of human immunodeficiency virus infections, the growing boom in immunomodulatory therapy and the use of broad-spectrum antibiotics for long periods of time have become the most important risk factors for the increasing incidence of infections by microorganisms of the genus Candida. Due to this, knowledge of this disease and its most important clinical forms, as well as the current diagnostic approach and treatment, is imperative; information that we collect in this document to provide an overview of this condition(AU)
Asunto(s)
Humanos , Candidiasis/etiología , Candidiasis Cutánea/diagnóstico , Candidiasis Vulvovaginal/diagnóstico , Factores de Riesgo , Candida albicans , Incidencia , Esofagitis , InmunomodulaciónRESUMEN
INTRODUCTION AND OBJECTIVES: The use of anticoagulants to prevent embolic events in Spain is very high, tending to a progressive increase. For this reason, we intend to analyse the mortality of patients from a metropolitan area of Granada treated with vitamin K antagonist anticoagulants (VKA), over 2 non-consecutive years. PATIENTS AND METHODS: Longitudinal, observational, retrospective study of 205 patients treated with VKA. Sociodemographic data, previous clinical conditions, pathology causing VKA treatment, degree of control and mortality were collected 2 years after the start of the study. RESULTS: Average age, 76±11.8 years (57.56% women). Two-year mortality was 22.4%, with a significant increase depending on age (p<.001) and years of treatment (p<.001). Patients with dementia (p<.05), with chronic kidney disease (p<.01) or with chronic obstructive pulmonary disease (p<.01) also presented higher mortality. Multivariate analysis showed significant effect of chronic kidney disease (odds ratio=4.075), chronic obstructive pulmonary disease (odds ratio=3.694), and years of treatment (odds ratio=1.236). CONCLUSIONS: At 2 years of follow-up, 1 in 5 patients treated with VKA died. The presence of chronic kidney disease, chronic obstructive pulmonary disease and a longer treatment time were independently associated with this increase of mortality. Most of the patients were anticoagulated by atrial fibrillation, they were elderly and had a high prevalence of comorbidities.
Asunto(s)
Fibrilación Atrial , Accidente Cerebrovascular , Administración Oral , Anciano , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Atención Primaria de Salud , Estudios Retrospectivos , Vitamina KRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Infecciones por Coronavirus/diagnóstico , Neumonía Viral/diagnóstico , Pandemias , Reacción en Cadena de la Polimerasa , RecurrenciaRESUMEN
Scar tissue size following myocardial infarction is an independent predictor of cardiovascular outcomes, yet little is known about factors regulating scar size. We demonstrate that collagen V, a minor constituent of heart scars, regulates the size of heart scars after ischemic injury. Depletion of collagen V led to a paradoxical increase in post-infarction scar size with worsening of heart function. A systems genetics approach across 100 in-bred strains of mice demonstrated that collagen V is a critical driver of postinjury heart function. We show that collagen V deficiency alters the mechanical properties of scar tissue, and altered reciprocal feedback between matrix and cells induces expression of mechanosensitive integrins that drive fibroblast activation and increase scar size. Cilengitide, an inhibitor of specific integrins, rescues the phenotype of increased post-injury scarring in collagen-V-deficient mice. These observations demonstrate that collagen V regulates scar size in an integrin-dependent manner.
Asunto(s)
Cicatriz/metabolismo , Colágeno Tipo V/deficiencia , Colágeno Tipo V/metabolismo , Lesiones Cardíacas/metabolismo , Contracción Miocárdica/genética , Miofibroblastos/metabolismo , Animales , Cicatriz/genética , Cicatriz/fisiopatología , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Cadena alfa 1 del Colágeno Tipo I , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Colágeno Tipo V/genética , Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Femenino , Fibrosis/genética , Fibrosis/metabolismo , Regulación de la Expresión Génica/genética , Integrinas/antagonistas & inhibidores , Integrinas/genética , Integrinas/metabolismo , Isoproterenol/farmacología , Masculino , Mecanotransducción Celular/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microscopía de Fuerza Atómica/instrumentación , Microscopía Electrónica de Transmisión , Contracción Miocárdica/efectos de los fármacos , Miofibroblastos/citología , Miofibroblastos/patología , Miofibroblastos/ultraestructura , Análisis de Componente Principal , Proteómica , RNA-Seq , Análisis de la Célula IndividualRESUMEN
Introduction: Aspiration pneumonia is a subclass of community-acquired pneumonia that is expected to have an increasing contribution in mortality and morbidity, particularly in the elderly population over the next coming decades. While studies have revealed significant progress in identifying risk factors for aspiration pneumonia, the clinical presentation and diagnosis remain challenging to healthcare providers. Areas covered: We conducted a broad literature review using the MeSH heading in PubMed/MEDLINE of 'aspiration pneumonia' from January 1970 to July 2019. The understanding of the microbiology of aspiration pneumonia has evolved from a possible shift in the causative organisms away from anaerobes to traditional community-acquired pneumonia organisms. The importance of this shift is not yet known, but it has questioned the pathogenic role of anaerobes, appropriate anaerobic testing and the role of these pathogens in the pulmonary microbiome in patients with pneumonia. The identification of risk factors led to strategies to prevent or minimize the risk of aspiration pneumonia with moderate success. Expert opinion: Our expert opinion is that further research is needed to determine the role of the microbiome with aspiration pneumonia and patient risk factors. There is also a great need to develop clinical tools to help providers diagnose, treat, and prevent aspiration pneumonia.
Asunto(s)
Infecciones Comunitarias Adquiridas/prevención & control , Neumonía por Aspiración/prevención & control , Neumonía Bacteriana/prevención & control , Anciano , Bacterias Anaerobias/aislamiento & purificación , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/microbiología , Humanos , Neumonía por Aspiración/etiología , Neumonía por Aspiración/microbiología , Neumonía Bacteriana/etiología , Neumonía Bacteriana/microbiología , Factores de RiesgoRESUMEN
Este documento tiene por objetivos resumir los desafíos actuales de la medicina familiar en América Latina y proponer posibles líneas de acción para consolidar su desarrollo. En los últimos 40 años, los sistemas de salud de la Región de las Américas han encarado reformas cuyos resultados fueron negativos en términos de equidad, y la atención primaria de la salud, lejos de ser aquella estrategia destinada a reducirla, se restringió a una política focal y selectiva. En este contexto, las propuestas técnicas de expansión de las plazas de formación en medicina familiar y su inserción en las carreras de Medicina, han carecido de coherencia y de una dirección política clara, por lo que su falta de eficacia puede leerse como un síntoma de estas reformas incompletas. Al respecto, la Confederación Iberoamericana de Medicina Familiar realizó recomendaciones sobre el compromiso político de los gobiernos para asegurar la estructura y el financiamiento necesarios, consolidar el modelo de medicina familiar como mecanismo de instrumentación de la atención primaria de la salud, la jerarquización de los programas de formación, las condiciones laborales de los médicos de familia y la certificación profesional, entre otras. Estas recomendaciones técnicas, sin acción política coherente y oportuna, no serán más exitosas que los intentos previos.(AU)
This article summarizes the current challenges of family medicine in Latin America and proposes possible lines of action to consolidate its development. In the last 40 years, the health systems of the Region of the Americas have faced reforms whose results were negative in terms of equity, and primary health care, far from being a strategy designed to reduce it, was restricted to a selective and focal policy. In this context, the technical proposals for expansion of training positions in family medicine and their insertion in medical careers have lacked consistency and a clear political direction, and thus their lack of effectiveness can be considered a symptom of these incomplete reforms. In this regard, the Ibero-American Confederation of Family Medicine made recommendations on the political commitment of governments to ensure the necessary structure and funding, consolidate the model of family medicine as a mechanism for the implementation of primary health care, the hierarchy of programs of training, the working conditions of family doctors and professional certification, among others. These technical recommendations, without a consistent and timely political action, will not be more successful than previous attempts.(AU)
Este documento tem como objetivo resumir os desafios atuais da medicina familiar na América Latina e propor possíveis linhas de ação para consolidar seu desenvolvimento. Nos últimos 40 anos, os sistemas de saúde da Região das Américas encararam reformas cujos resultados foram negativos em termos de igualdade, e a atenção primária à saúde, longe de sê-la aquela estratégia destinada a reducir-la, restringiu-se a uma política focal e seletiva. Neste contexto, as propostas técnicas de expansão das praças de formação em medicina familiar e sua inserção nas carreiras de Medicina, não dispuseram de coerência e de uma direção política clara, razão pela qual sua falta de eficácia se pode ler como um sintoma destas reformas incompletas. Neste sentido, a Confederação Ibero-americana de Medicina Familiar realizou recomendações sobre o compromisso político dos governos a fim de assegurar a estrutura e o financiamento necessários, consolidar o modelo de medicina familiar como mecanismo de instrumentação da atenção primária à saúde, a hierarquização dos programas de formação, as condições laborais dos médicos de família e a certificação profissional, entre outras. Estas recomendações técnicas, sem ação política coerente e oportuna, não serão mais exitosos que as tentativas prévias.(AU)